Tuesday, March 8, 2011

Stem Cell Therapeutics Corp. Announces Commencement of MS Research Program
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") is pleased to announce today that the Multiple Sclerosis (MS) phase II clinical trial is proceeding. This program will be executed by the University of Calgary utilizing funding from the Stem Cell Network, based in Ottawa. The financial commitment of SCT is limited...Click here to read article
Bookmark and Share